Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer? An algorithm for assessment of impact of axillary dissection

Annals of Surgery

Volumn 226, Issue 3, 1997, Pages 279-287

  Dees, Elizabeth Claire ^a   Shulman, Lawrence N ^a   Souba, Wiley W ^a   Smith, Barbara L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FALSE NEGATIVE REACTIONS; FEMALE; FLUOROURACIL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY, RADICAL; MASTECTOMY, SEGMENTAL; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TAMOXIFEN;

EID: 0031420231     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199709000-00007     Document Type: Article

References (27)

1. Fisher B, Redmond C, Fisher ER, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312:674- 681.
2. Cabanes PA, Salmon RJ, Vilqoc, J et al. Value of axillary dissection in addition to lumpectomy and radiotherapy in early breast cancer. Lancet 1992; 339: 1245-1248.
3. Fisher B, Wolmark N, Bauer M, et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981; 152:765-772.
4. Petrek JA, Blackwood MM. Axillary dissection: current practice and technique. Curr Probl Surg 1995; 32:25-32.
5. Osteen RT, Smith BL. Results of conservative surgery and radiation therapy for breast cancer. Surg Clin North Am 1990; 70:1005- 1021.
6. Atkins H, Hayward JL, Klugman D, et al. Treatment of early breast cancer: a report after ten years of a clinical trial. Br Med J 1972; 2:423-427.
7. Johnsen C. Breast disease. A clinical study with special reference to diagnostic procedures. Acta Chir Scand Suppl 1975;454:1-108.
8. Wallace IW, Champion HR. Axillary nodes in breast cancer. Lancet 1972; 1:692.
9. Danforth DN Jr, Findlay PA, McDonald HD, et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. J Clin Oncol 1986; 4:655-662.
10. Wazer DE, Erban JK, Robert NJ, et al. Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection. Cancer 1994; 74:878-883.
11. Silverstein MJ, Giersen ED, Waisman JR, et al. Axillary lymph node dissection for T1a carcinoma. Is it indicated? Cancer 1994; 73:664-667.
12. Haffty BG, Ward B, Pathare P, et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997; 15:691-700.
13. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995; 76:1491-1512.
14. Copeland EM. Is axillary dissection necessary for T1 carcinoma of the breast? J Am Coll Surg 1997; 184:397-398.
15. Ravdin PM, De Laurentis M, Vendely, et al. Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators. J Natl Cancer Inst 1994; 86:1771-1775.
16. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. N Engl J Med 1995; 332:901-906.
17. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage 2, node-positive breast carcinoma. N Engl J Med 1994; 330:1253-1259.
18. Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 1992; 52:2127-2137.
19. Glick JH, Gelber RD, Goldhirsch A, Senn HJ. Meeting highlights: adjuvant therapy for primary breast cancer. J Natl Cancer Inst 1992; 84:1479-1485.
20. Hortobagyi GN, Buzdar AU. Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. CA Cancer J Clin 1995;45:199-226.
21. Carter CL, Allen C, Henson DE, et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63:181-187.
22. Chadha M, Chabon AB, Friedmann P, Vikram B. Predictors of axillary lymph node metastases in patients with T1a breast cancer: a multivariate analysis. Cancer 1994; 73:330-353.
23. Stierer M, Rosen HR, Weber R, et al. Long term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet 1992; 175:151-160.
24. Rose CM, Botnick LE, Weinstein M, et al. Axillary sampling in the definitive treatment of breast cancer by radiation therapy and lumpectomy. Int J Radiat Oncol Biol Phys 1983; 9:339-344.
25. Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. J Am Med Assoc 1996; 276:1818-1822.
26. Giuliano AE, Kirgan DM, Guenther JM, Morton DL, Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220:398-401.
27. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and rudiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2:335-340.